Clinical Trials Logo

Filter by:
NCT ID: NCT05849272 Not yet recruiting - Somatic Symptom Clinical Trials

Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression

Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of somatic symptoms in depression, to provide evidence-based basis for clinical rational drug use.

NCT ID: NCT05849246 Not yet recruiting - Clinical trials for Non-squamous Non-small-cell Lung Cancer

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Start date: May 30, 2023
Phase: Phase 2
Study type: Interventional

Primary objective: ·To assess the antitumor activity of tusamitamab ravtansine in combination with sintilimab and tusamitamab ravtansine in combination with sintilimab, platinum-based chemotherapy and pemetrexed in the NSQ NSCLC population. Secondary objectives: To assess the safety and tolerability of tusamitamab ravtansine in combination with sintilimab and tusamitamab ravtansine in combination with sintilimab, platinum-based chemotherapy and pemetrexed in the NSQ NSCLC population. To assess the pharmacokinetic (PK) characteristic of tusamitamab ravtansine in combination with sintilimab and tusamitamab ravtansine in combination with sintilimab, platinum-based chemotherapy and pemetrexed in the NSQ NSCLC population.

NCT ID: NCT05848934 Not yet recruiting - Clinical trials for Coronary Heart Disease

Research on the Relationship Between Cognitive Function Changes and Cerebrovascular Health in Patients With Coronary Heart Disease

Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to elucidate the imaging mechanisms of cognitive function changes in patients with coronary heart disease before and after surgery or conservative treatment, and to evaluate and predict the postoperative neurological function recovery and cerebrovascular health level of patients by combining serum markers and patient cardiovascular health evaluation indicators.

NCT ID: NCT05848921 Not yet recruiting - Clinical trials for Carotid Artery Stenosis

Evaluation of Brain Health and Surgical Efficacy in Patients With Carotid Artery Stenosis

Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to explore the relationship between the recovery of cerebrovascular morphology and cognitive function before and after surgical treatment in patients with carotid artery stenosis and their preoperative cardiac health status. And combined with preoperative cognitive status, serum markers, and cardiovascular health evaluation indicators, evaluate and predict the possibility of postoperative neurodegenerative diseases and the level of cerebrovascular health in patients.

NCT ID: NCT05848154 Not yet recruiting - Clinical trials for Patients With Non-metastatic Pancreatic Cancer

Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer

Start date: June 1, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the value of ctDNA detection in the assessment of response rate to neoadjuvant chemotherapy in pancreatic cancer and to explore the correlation between ctDNA clearance and prognosis at different time points. Meanwhile, whole exome sequencing (WES) and RNA Sequencing (RNA-seq) of samples of responders and non-responders to neoadjuvant chemotherapy before and after treatment are performed to explore the mechanisms of drug resistance and provide guidance for clinical decision making.

NCT ID: NCT05847894 Not yet recruiting - Clinical trials for Artificial Intelligence

Assisting Pulmonary Disease Diagnosis With Ophthalmic Artificial Intelligence Technology

Start date: July 2023
Phase:
Study type: Observational [Patient Registry]

This study intends to collect ophthalmologic examination results, pulmonary examination results and related indexes from patients with pulmonary disease and control populations, and combine big data analysis and artificial intelligence technology to explore whether new methods can be provided for early screening strategies for pulmonary disease with the aid of ophthalmologic examination, and thus assist in identifying the types of pulmonary disease and determining disease prognosis.

NCT ID: NCT05847764 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Start date: May 2023
Phase: Phase 2
Study type: Interventional

Disitamab Vedotin combined therapy locally advanced or metastatic NSCLC Patients with HER2 Alterations.

NCT ID: NCT05846867 Not yet recruiting - Colorectal Cancer Clinical Trials

Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients

Start date: May 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II clinical study on AK119 and AK112 combined with or without chemotherapy in advanced microsatellite stabilized (pMMR/MSS) colorectal cancer

NCT ID: NCT05845723 Not yet recruiting - Aneurysm Clinical Trials

Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

This project aims to evaluate the efficacy and safety of the combination of glucocorticoids with tocilizumab or tofacitinib, compared to the traditional combination of glucocorticoids with cyclophosphamide in the treatment of vascular Behçet's syndrome.

NCT ID: NCT05845372 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy

Start date: May 1, 2023
Phase:
Study type: Observational

Ischemic stroke accounts for a relatively high proportion of strokes. In recent years, intravenous thrombolysis and endovascular therapy have significantly improved the revascularization rate in patients with large vessel occlusive cerebral infarction, but 20-50% of patients still experience ineffective revascularization. Therefore, postoperative monitoring and treatment of patients with large vessel occlusions is crucial for early recognition, management and prevention of complications. Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, and a previously proven incidence of stress ulcer bleeding after ischemic stroke. Stress ulcer bleeding after ischemic stroke has been shown to be closely associated with unfavorable outcomes, such as mortality. Current national and international guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for the prevention of stress ulcers, but rather should be considered in the context of the patient's risk factors for stress ulcers and discontinued after the patient initiates enteral nutrition. However, there is no evidence-based medical evidence to support the risk-benefit relationship of stress ulcer drug prophylaxis in patients with mechanical thrombectomy for acute anterior circulation large vessel occlusion.